Targeting Therapeutics for the Middle and Inner Ear - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Targeting Therapeutics for the Middle and Inner Ear
A Conversation with Otonomy

Pharmaceutical Technology

PharmTech» Can other APIs be delivered this way?

»LeBel: Yes. The platform is very flexible and theoretically can be used for local delivery of small-molecule antibiotics to treat infections as well as small-molecule glutamate receptor antagonists to help treat certain kinds of hearing loss. In addition, we think it can be used to deliver larger molecule neurotrophic factors such as brain-derived neurotrophic factor or glial-cell line derived neurotrophic factor, which may alo be useful in treating hearing loss. We also imagine that we can combine the basic poloxamers with additional ingredients (e.g., permeabilizing agents, bulking agents, stabilizers, or solubilizers) as needed to optimize drug delivery.

PharmTech» Could this formulation be used to treat diseases in other organs?

»LeBel: Poloxamers are used in other pharmaceutical preparations to deliver drugs to the eye, gums, and abdomen. However, we're dedicated to treatments for inner- and middle-ear disorders at this time.

* defines Meniere's disease as follows: Meniere's disease is a disorder of the inner ear that causes abnormal sensory perceptions, including a sensation of a spinning motion (vertigo), hearing loss usually in one ear, fullness or pressure in the same ear, and ringing in the same ear (tinnitus). People in their 40s and 50s are more likely than people in other age groups to develop Meniere's disease. Estimates of the number of people with Meniere's disease vary significantly, but according to the National Institute on Deafness and Other Communication Disorders, about 615,000 people in the United States have the disease.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here